Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended-release tacrolimus versus tacrolimus capsules after adult DCD liver transplantation
ChiCTR1900020719Phase 4Recruiting
- Sponsor
- Shulan Health
- Start
- Jan 2018
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tacrolimus in liver transplant (2 arms), sponsored by Shulan Health. Primary endpoint: Incidence of biopsy-proven acute rejection within 30 days after liver transplantation. Started Jan 2018; status: recruiting.
02
Drugs
tacrolimus
03
Conditions
liver transplant
Beyond the preview
Go deeper on ChiCTR1900020719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900020719.